| Alkermes jumps; Cerus, InterMune slide | 11/17/2009 - 11:20 |
| Isis Cholesterol Drug Effective, but Safety a Worry | 11/17/2009 - 11:14 |
| InterMune Hep C Drug Hit With Liver Tox Worry | 11/17/2009 - 11:06 |
| FDA says Prilosec can block benefits of Plavix | 11/17/2009 - 11:05 |
| WuXi Pharma Feels the Worst of the Downturn Is Over | 11/17/2009 - 11:04 |
| AstraZeneca Heartburn Pills Are Tied to Deaths in Artery Clearing | 11/17/2009 - 11:02 |
| Roche applies for Avastin advanced breast cancer use | 11/17/2009 - 10:45 |
| Novartis: Smaller flu-vaccine doses suffice | 11/17/2009 - 10:32 |
| As Tax Breaks for Pfizer End, Jobs Disappear | 11/17/2009 - 09:56 |
| Bristol Exchange Eases Downsizing | 11/17/2009 - 09:39 |
| Mead Johnson May Become Bid Target for Danone, Nestle, Heinz | 11/17/2009 - 09:18 |
| New Vaccine Questioned (Pfizer) | 11/17/2009 - 09:10 |
| Merck shares rise as Wall Street brushes off study comparing cholesterol drugs Niaspan, Zetia | 11/16/2009 - 18:44 |
| Getting to the Heart of the Merck-Abbott Embargo Break | 11/16/2009 - 18:44 |
| Bristol-Myers shares jump on news of Mead Johnson split | 11/16/2009 - 18:43 |
| NeurogesX receives Food and Drug Administration approval for Qutenza pain patch | 11/16/2009 - 17:36 |
| Contamination Issues Haunt Genzyme | 11/16/2009 - 11:08 |
| A Closer Look at Cardium's Wound-Healing Drug | 11/16/2009 - 11:07 |
| Par Pharma gets FDA nod for generic version of Ultram | 11/16/2009 - 10:41 |
| Bristol-Myers, Merck lead drug stocks higher | 11/16/2009 - 10:35 |
| Fate Therapeutics Seals $30 M Series B, Gets Corporate Venture On Board | 11/16/2009 - 10:33 |
| Human Genome's anthrax drug denied approval | 11/16/2009 - 10:32 |
| Cell Therapeutics Lavishes Free Stock on Execs | 11/16/2009 - 10:29 |
| An Odd Mix: Health Care Reform & Higher Rx Prices | 11/16/2009 - 10:01 |
| Poniard Pharma says picoplatin did not improve survival in late stage study; shares tumble | 11/16/2009 - 09:59 |
| [video] Cholesterol Drug Battle: Merck vs. Abbott Labs | 11/16/2009 - 09:25 |
| Lilly's new development star signals strategic shift | 11/16/2009 - 09:23 |
| Playing the Options Game in RIM; Cel Sci Not Yet Trading to Its Potential | 11/16/2009 - 09:22 |
| GlaxoSmithKline could pay Nabi more than $500 million in deal to develop anti-smoking vaccines | 11/16/2009 - 09:11 |
| Bayer, Novartis, Sanofi-Aventis Rated New ‘Buy’ at Deutsche Bank | 11/16/2009 - 09:10 |
